Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
Phase 1 Completed
104 enrolled
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
Phase 1 Completed
29 enrolled
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma
Phase 1 Completed
65 enrolled
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Phase 1 Completed
27 enrolled
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2 Completed
95 enrolled 13 charts
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Phase 1 Completed
91 enrolled
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
Phase 1 Completed
13 enrolled
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
Phase 1/2 Completed
81 enrolled
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL
Phase 1 Completed
90 enrolled 27 charts
Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia
Phase 3 Completed
365 enrolled 28 charts
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Phase 2 Completed
199 enrolled 14 charts
TLN-Registry
Completed
3,795 enrolled
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Phase 1 Completed
20 enrolled
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
Phase 1 Completed
52 enrolled
RETRO-idel
Completed
112 enrolled
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects
Phase 1 Completed
12 enrolled
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia
Phase 2 Completed
10 enrolled 35 charts
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Phase 2 Completed
99 enrolled 27 charts
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 1 Completed
40 enrolled
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
Phase 2 Completed
10 enrolled 52 charts
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
Phase 1 Completed
123 enrolled
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Phase 1 Completed
33 enrolled 13 charts
Phase IV Observational Study in Chronic Lymphocytic Leukemia
Completed
1 enrolled
AZD6738 First Time in Patient Multiple Ascending Dose Study
Phase 1 Completed
2 enrolled
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
Phase 2 Completed
223 enrolled 31 charts
Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
Phase 4 Completed
29 enrolled 18 charts
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Phase 1/2 Completed
133 enrolled 10 charts
BIFROST
Phase 2 Completed
61 enrolled 22 charts
Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL)
Completed
300 enrolled
PCYC-04753
Phase 1 Completed
66 enrolled
A Phase I Extension Trial of Repeated Infusions of ISF35
Phase 1 Completed
4 enrolled
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
Phase 1 Completed
9 enrolled